KNIGHT CAPITOL CONSULTANTS for REGENXBIO
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Potential changes in the corporate tax rate or other provisions of interest to business (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch. |
Health Issues HCR
Potential legislation implementing value based purchasing for pharmaceuticals (no specific bill); Possible provisions of Drug Pricing Legislation (H.R. 3, H.R. 19, S. 2543 and successor legislation) that affect biological products' development and marketing. Possible authority for a new ARPA-H.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch |
Medicare/Medicaid MMM
Inclusion of provisions affecting the reimbursement of gene therapies that may be included in any drug pricing legislation or legislation on infrastructure (no specific bills)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Pharmacy PHA
Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.